An astrocytoma is a tumor that grows from star-shaped brain cells called astrocytes, which normally provide structural support and nutrients to neurons in your central nervous system. These tumors range from slow-growing and highly treatable (grade 1) to aggressive and life-threatening (grade 4, also known as glioblastoma). Astrocytomas are the most common type of glioma, the broad category of tumors that arise from the brain’s supportive tissue.
How Astrocytomas Develop
Astrocytes are glial cells, meaning they form the scaffolding that holds your brain and spinal cord together. They help regulate blood flow to the brain, maintain the chemical environment neurons need to fire properly, and assist in repairing damaged tissue. When these cells grow out of control, the result is an astrocytoma.
A key discovery in recent years involves a mutation in the IDH1 gene, which normally helps cells produce energy. When this gene mutates, it produces a chemical called 2-HG that accumulates inside healthy astrocytes over time. This buildup gradually transforms the cells into abnormal, tumor-forming ones. The presence or absence of this IDH mutation is now one of the most important factors in classifying and predicting the behavior of these tumors.
Grades and What They Mean
The World Health Organization classifies astrocytomas into four grades based on how abnormal the cells look under a microscope and what genetic changes they carry. The 2021 classification system uses Arabic numerals (1, 2, 3, 4) and places heavy emphasis on molecular features, not just what the tumor looks like.
Grade 1 (pilocytic astrocytoma) is the most common brain tumor in children between ages 5 and 14, accounting for about 20% of all childhood central nervous system tumors. These tumors grow slowly, are often well-defined, and can frequently be cured with surgery alone. The five-year survival rate is around 96%.
Grade 2 tumors are slow-growing but infiltrate surrounding brain tissue, making them harder to remove completely. They carry an IDH mutation, which is actually a favorable sign compared to tumors without one. Median survival is about 7 to 8 years, and combined radiation and chemotherapy has improved outcomes significantly compared to radiation alone.
Grade 3 tumors show more aggressive cell growth and division. They also carry the IDH mutation but behave more unpredictably. Median survival is approximately 5 years.
Grade 4 represents the most aggressive form. If the tumor carries an IDH mutation, it’s classified as astrocytoma, IDH-mutant, grade 4. If it lacks the mutation (called IDH-wildtype), it’s classified as glioblastoma. Glioblastoma is the most common and deadly primary brain tumor in adults, with a median survival of about 14 to 15 months. Even tumors that appear low-grade under the microscope can be upgraded to grade 4 if they carry certain aggressive molecular features, because those tumors behave just as poorly as classic glioblastoma regardless of how they look.
IDH Mutation and Tumor Classification
The IDH mutation status has become the single most important dividing line in how these tumors are classified and treated. An IDH-mutant astrocytoma, even at higher grades, generally carries a better prognosis than an IDH-wildtype tumor. This molecular marker also helps doctors distinguish astrocytomas from oligodendrogliomas, the other major type of diffuse glioma. Oligodendrogliomas carry both the IDH mutation and a specific chromosomal change called 1p/19q codeletion. Astrocytomas lack that codeletion. The old category of “mixed oligoastrocytoma” no longer exists under the current classification because molecular testing can now reliably sort tumors into one category or the other.
Symptoms by Tumor Location
Astrocytoma symptoms depend almost entirely on where the tumor sits and how fast it’s growing. Slow-growing tumors can go undetected for months or years, producing subtle changes that are easy to overlook. A first-time seizure is often the earliest sign, particularly for grade 2 tumors. Other early symptoms include mild headaches, difficulty finding the right words, and subtle shifts in mood, memory, or concentration.
As the tumor grows, symptoms become more pronounced:
- Cerebral hemispheres (top of the brain): Weakness on one side of the body, speech or vision problems, personality changes, worsening memory
- Cerebellum (back and lower brain): Poor balance, unsteady walking, stumbling, nausea and vomiting from rising pressure inside the skull
- Brainstem: Double vision, facial weakness or numbness, difficulty swallowing
- Spinal cord: Pain in the neck or back that develops gradually, tingling or numbness radiating into an arm or leg, weakness in the limbs, bowel or bladder changes
Headaches that worsen in the morning or with coughing and straining are a hallmark of increased pressure inside the skull, which happens when the tumor itself, or swelling around it, compresses brain tissue or blocks the flow of cerebrospinal fluid.
How Astrocytomas Are Diagnosed
MRI is the primary imaging tool. On standard MRI sequences, astrocytomas typically appear as bright areas on T2-weighted images. Lower-grade tumors usually don’t light up with contrast dye, while higher-grade tumors often do, reflecting the leaky, abnormal blood vessels that aggressive tumors develop. This contrast pattern gives doctors an initial clue about the tumor’s grade, but it isn’t definitive.
Imaging alone cannot confirm the diagnosis. A tissue sample, obtained either through a surgical biopsy or during tumor removal, is necessary to determine the tumor’s exact type and grade. That tissue undergoes both microscopic examination and molecular testing to identify mutations like IDH and chromosomal changes. These molecular results drive treatment decisions and provide a much clearer picture of prognosis than the microscope alone.
Treatment Approaches
Surgery is the first step for nearly all astrocytomas when it can be done safely. The goals are to remove as much tumor as possible and to obtain tissue for diagnosis. For high-grade tumors, removing more than 98% of the visible tumor on MRI improves median survival from roughly 9 months to 13 months. For low-grade tumors, some evidence suggests that removing tissue beyond the MRI-visible boundaries of the tumor may further improve long-term outcomes. When a tumor sits in a critical area of the brain where surgery would cause unacceptable damage, a stereotactic needle biopsy can retrieve a small tissue sample for diagnosis instead.
After surgery, treatment depends on the grade. For low-grade astrocytomas considered high-risk (larger tumors, incomplete resection, or older patients), a combination of radiation therapy followed by chemotherapy has become the standard approach. A phase II study of this combination in high-risk low-grade astrocytomas reported a median overall survival of 8.2 years, with 61% of patients alive at five years and about 35% at ten years. These numbers exceeded historical results from radiation alone.
For higher-grade tumors, radiation with concurrent and follow-up chemotherapy is standard. The specific chemotherapy regimen and duration are tailored based on tumor grade and molecular profile.
In children with low-grade gliomas that come back after initial treatment, newer targeted therapies have recently become available. The FDA approved a drug targeting a specific genetic alteration (BRAF fusion or mutation) in pediatric patients in April 2024, offering an option for children as young as six months old whose tumors carry that change.
Children vs. Adults
Pilocytic astrocytomas (grade 1) are overwhelmingly a pediatric disease. In a large analysis of over 4,300 patients, about 69% were children. Pediatric pilocytic tumors are more likely to develop in the cerebellum, tend to be larger at diagnosis, and are more often fully resected. Adult pilocytic astrocytomas, by contrast, are more likely to occur in locations outside the cerebellum, are less often completely removed, and carry a worse prognosis.
Higher-grade astrocytomas affect adults more commonly, with glioblastoma peaking in people over 50. The biology of these tumors differs between age groups as well. IDH-mutant tumors are more common in younger adults, generally appearing between ages 25 and 45, while IDH-wildtype glioblastoma predominates in older adults and behaves more aggressively.
Outlook by Grade
Survival varies dramatically across the four grades. Grade 1 pilocytic astrocytomas are often curable, with a five-year survival rate of approximately 96%. Grade 2 tumors carry a median survival of 7 to 8 years, though many patients live well beyond that with modern treatment combining radiation and chemotherapy. Grade 3 tumors have a median survival of about 5 years. Grade 4 tumors, particularly IDH-wildtype glioblastoma, remain the most challenging, with a median survival of roughly 14 to 15 months despite aggressive treatment.
These numbers are population-level medians, meaning half of patients do better and half do worse. Individual prognosis depends on tumor location, how much can be safely removed, molecular features like IDH status, and the patient’s age and overall health. The growing role of molecular classification has made these predictions more precise than they were even a decade ago, and targeted therapies based on specific mutations are beginning to shift outcomes for certain subtypes.